When tPA was administered to MCAO mouse models outside of its therapeutic window, the subsequent administration of human NSCs reduced the impact of ischemia-reperfusion injury, suggesting synergistic effects with other stroke therapies [34]. This evidence concerns the gene PLAT and stroke disorder.